Core Biogenesis uses plants as biofactories to scale the production of high-value bioproducts. Their incredibly scalable bioproduction-as-a-service platform accelerates mass production and increases yields while driving down costs.
Growth factors control the maintenance, proliferation, and differentiation of cells and represent a key tool in stem cell research and regenerative medicine. Small differences in endotoxin contamination can have drastic effects on cell culture. Creating environments to test and produce these cells is incredibly expensive and difficult.
Core Biogenesis employs a novel green bioproduction platform to express recombinant proteins from plants. Their animal-free growth factors and cytokines contribute to a more cost-effective and commercially-viable cell therapy manufacturing process, supporting the treatment of neurodegenerative and cardiovascular diseases, and certain cancers. By unlocking a new paradigm in recombinant molecule production, they are helping build a more sustainable future.
Alexandre has a background in Biotechnology and Neuroscience, and experience as a project manager in neurotechnology. He holds a Bachelor’s Degree in Biomedical Science from Universite de Strasbourg, and a Master’s Degree in Neuroscience from Albert-Ludwigs-Universität Freiburg im Breisgau.
Founded at Entrepreneur First
Seed ($2.6 million) led by XAnge
Series A ($10.5 million) led by XAnge